Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $973.13 Consensus Price Target from Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned a consensus recommendation of “Moderate Buy” from the twenty-five brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $973.13.

Several research firms recently commented on REGN. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Citigroup lowered their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $710.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. The stock has a market capitalization of $78.02 billion, a PE ratio of 18.55, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a fifty day moving average of $715.81 and a two-hundred day moving average of $910.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $11.86 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in REGN. AGF Management Ltd. raised its position in shares of Regeneron Pharmaceuticals by 281.2% in the 4th quarter. AGF Management Ltd. now owns 1,277 shares of the biopharmaceutical company’s stock valued at $910,000 after purchasing an additional 942 shares in the last quarter. Wealthfront Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 68.5% in the fourth quarter. Wealthfront Advisers LLC now owns 15,990 shares of the biopharmaceutical company’s stock worth $11,390,000 after buying an additional 6,501 shares during the last quarter. Cornerstone Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 31.7% in the fourth quarter. Cornerstone Advisors LLC now owns 7,900 shares of the biopharmaceutical company’s stock valued at $5,627,000 after acquiring an additional 1,900 shares in the last quarter. Mcdonald Capital Investors Inc. CA boosted its stake in Regeneron Pharmaceuticals by 24.7% during the 4th quarter. Mcdonald Capital Investors Inc. CA now owns 170,180 shares of the biopharmaceutical company’s stock valued at $121,224,000 after acquiring an additional 33,727 shares during the last quarter. Finally, Independent Advisor Alliance grew its holdings in Regeneron Pharmaceuticals by 117.3% during the 4th quarter. Independent Advisor Alliance now owns 478 shares of the biopharmaceutical company’s stock worth $340,000 after acquiring an additional 258 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.